Part II: Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation

  • John J. Parlow
  • , Mary W. Burney
  • , Brenda L. Case
  • , Thomas J. Girard
  • , Kerri A. Hall
  • , Peter K. Harris
  • , Ronald R. Hiebsch
  • , Rita M. Huff
  • , Rhonda M. Lachance
  • , Deborah A. Mischke
  • , Stephen R. Rapp
  • , Rhonda S. Woerndle
  • , Michael D. Ennis

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Efforts to refine the SAR of the piperazinyl-glutamate-pyridines for more potent analogs with improved pharmacokinetic profiles are described. Exploring substituted piperidines and other ring systems at the 4-pyridyl position led to compounds with improved potency and pharmacokinetic properties over candidate I. In particular, compounds 4t and 5t were discovered with a 10-fold improvement over potency and improved pharmacokinetic profiles in both the rat and dog.

Original languageEnglish
Pages (from-to)1388-1394
Number of pages7
JournalBioorganic and Medicinal Chemistry Letters
Volume20
Issue number4
DOIs
StatePublished - Feb 15 2010

Keywords

  • Antiplatelet
  • Antithrombotic
  • Cardiovascular disease
  • GPCR antagonist
  • P2Y12 receptor

Fingerprint

Dive into the research topics of 'Part II: Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation'. Together they form a unique fingerprint.

Cite this